Karyopharm Therapeutics (KPTI) PT Raised to $19 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
Karyopharm Therapeutics (KPTI) PT Raised to $22 at Baird; 'Expect a transformational year'
March 15, 2018 2:01 PM EDTBaird raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $22.00 (from $15.00) while maintaining a Outperform rating.
Analyst Michael E. Ulz commented, "Recent progress across the selinexor franchise was highlighted, and management indicated initial commercial preparations are underway, a positive sign, in... More
Karyopharm Therapeutics (KPTI) Misses Q4 EPS by 15c
March 15, 2018 7:01 AM EDTNote: EPS may not be comparable
Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($0.80), $0.15 worse than the analyst estimate of ($0.65).
Financial Outlook
Based on current operating plans, Karyopharm expects that its existing cash, cash equivalents and investments will be sufficient to fund its... More
